Inhalable dry powder product (DPP) of mRNA lipid nanoparticles (LNPs) for pulmonary delivery

• DOI: 10.1007/s13346-023-01402-y
• Publication Date: 2023-08-01T14:01:56Z
• Authors: Ashish Sarode; Priyal Patel; Natalia Vargas-Mo...; Ayed Allawzi; Alisa Zhilin-Roth; Saswata Karmakar; Lianne Boeglin; Hongfeng Deng; Shrirang Karve; Frank DeRosa
• Keywords: 0303 health sciences; 03 medical and health sciences; Original Article

Abstract Pulmonary delivery of mRNA via inhalation is a very attractive approach for RNA-based therapy treatment lung diseases. In this work, we have demonstrated successful development an mRNA-lipid nanoparticle (LNP) dry powder product (DPP), wherein the LNPs were spray dried using hydroalcoholic solvent along with mannitol and leucine as excipients. The desired critical attributes DPP accomplished by varying excipients, lipid composition, concentration LNPs, weight percentage mRNA. Leucine alone or in combination improved formulation increasing yield well decreasing particle size. Intratracheal administration mice resulted luciferase expression trachea lungs indicating functional Our results show optimization administered form efficacious great promise future therapeutics Graphical